Budd-Chiari Syndrome

Monopoint system enables rapid access to the venous system Research to be presented at SNIS Cerebral Venous and CSF Disorders Summit SAN MATEO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the results of a first-of-its-kind multicenter study published in Stroke: Vascular and Interventional Neurology, which demonstrated the utility of the Monopoint® system in procedures to treat idiopathic intracranial hypertension (IIH).1 Physicians participating in the study noted that the Monopoint system successfully navigated tortuous patient anatomy and crossed the stenosis, offering improved trackability and sufficient catheter length to enable successful stent delivery. Intracranial hypertension (IIH) occurs when increased cerebrospinal fluid pressure or venous outflow obstruction leads to elevated intracranial pressure, causing headaches, visual disturbances, pulsatile tinnitus, cognitive and psychological symptoms. The annual incidence of IIH in the western world is approximately 0.9 per 100,000 persons (approximately 3,000 diagnoses per year in the U.S.), but primarily afflicts females with obesity.2 One potential treatment for IIH involves venous stenting and treats the IIH cases that are associated with a venous stenosis identified during imaging studies.3 Such treatment requires passing through tortuous vessels in the venous anatomy to deliver a stent. The retrospective, multicenter, observational study aimed to understand the effectiveness of using the Monopoint system to access the venous sinus, cross through stenosis and allow delivery of a stent. The study included 71 patient procedures which took place between January 2022 and December 2023 at 13 high volume neurovascular centers in the U.S. This is the first such study using the Monopoint system to facilitate venous sinus stenting. “Physicians participating in the study rated the Monopoint system as better than conventional approaches 93 percent of the time,” noted Tony Chou, M.D., founder and chief executive officer at Route 92 Medical. “The Monopoint system’s single axial setup and large bore catheter design makes it an ideal choice for complex neurovascular procedures, such as venous sinus stenting where physicians must navigate through tortuous anatomy and a stenosis to reach the target location.” The Monopoint system is comprised of the Base Camp® 8F Sheath, HiPoint® 88 catheter, and Tenzing® 8 delivery catheter, which solved length compatibility problems that occur with conventional systems. The study showed that the Monopoint system could support the deployment of relatively stiff stent systems. Such systems benefit from a large bore catheter which can reduce the need for complex multiaxial catheter access setups as well as over-the-wire exchange maneuvers. The variable catheter length of the Monopoint system and improved trackability through tortuous anatomy also supported the procedural success. “We demonstrated that the flexibility of the Monopoint system, with a simple set up and a variable length, is extremely helpful in venous sinus stenting procedures where crossing stenosis to place venous stents can be challenging with less adaptable solutions,” said Oded Goren, M.D., associate professor of neurosurgery and director of vascular and endovascular neurosurgery at Geisinger Medical Center, Danville, Penn. “As a result of their venous sinus stenting procedures, study participants experienced a range of clinical improvements including a reduction in headaches, pulsatile tinnitus, and papilledema.” Matthew Alexander, M.D., M.S., medical director at Sutter Medical Center Sacramento, will present the study at the Society of NeuroInterventional Surgery Cerebral Venous and CSF Disorders Summit being held March 19-21, 2025, in Honolulu, Hawaii. His presentation will be Friday, March 21, 2025, at 3:45 p.m. The stents referenced in this publication are not approved for venous stenting. To learn more about the Monopoint system and other Route 92 Medical neurovascular intervention products, visit www.route92medical.com. About Route 92 MedicalRoute 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering and innovative product design. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. ____________________________ 1 Goren, Oded, M.D. et. Al. “Venous Sinus Stenting Using a Ledge-Reducing Catheter, 0.088-in. Catheter-Extender With an External Single Point of Control: Technique and Multicenter Clinical Experience.” Stroke: Vascular and Interventional Neurology. March 2025. Available: https://www-ahajournals-org.libproxy1.nus.edu.sg/doi/epub/10.1161/SVIN.124.001627. 2 Chen, John and Michael Wall. “Epidemiology and Risk Factors for Idiopathic Intracranial Hypertension.” Int. Ophthalmol. Clin. Winter 2014. Available: https://pmc-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/articles/PMC3864361/. 3 Fargen, Kyle M. “Venous Stenting for Idiopathic Intracranial Hypertension: Lessons Learned from High Volume Practice.” Journal of NeuroInterventional Surgery. 2022. Available: https://jnis-bmj-com.libproxy1.nus.edu.sg/content/14/6/528. Media Contact Gwen Gordon gwen@gwengordonpr.com

Top-ranked pediatric hospital system with the lowest waitlist times marks historic milestone AURORA, Colo., Jan. 8, 2025 /PRNewswire/ -- Children's Hospital Colorado (Children's Colorado) has reached a historic milestone for its Liver Transplant Program, performing a record-breaking number of transplants in 2024. With 22 liver transplants completed, Children's Colorado surpassed the program's previous record of 20 transplants in 2021. As a nationally recognized transplant program, Children's Colorado has the only pediatric-focused, multi-specialty program in the Rocky Mountain region with the lowest waitlist times in the nation. It is one of only six pediatric transplant programs nationally with significant experience performing living donor liver transplants. This achievement reflects not only the steady growth of the Liver Transplant Program over the last decade but also the team's commitment to utilizing every available option possible to get children transplanted quickly, including grafts from directed living donors (donating to a specific person), non-directed living donors (donating to a stranger) and reduced-size or split grafts from deceased donors. "When I look at this data, it's striking to see that while living donors make up roughly 15% of pediatric liver transplants nationally, they account for 40% of transplants at Children's Colorado," said Dr. Amy Feldman, Medical Director of the Liver Transplant Program at Children's Colorado. "This highlights our unique expertise and experience in performing living donor liver transplants. With the help of our adult colleagues at the University of Colorado and the altruistic community, we are able to get kids transplanted before they experience significant morbidity and mortality." In 2024, patients traveling from out of state made up 43% of liver transplants performed at Children's Colorado, underscoring the program's regional and national impact. The breadth of diagnoses of children transplanted in 2024 – such as Wilson's disease, biliary atresia, acute liver failure, Budd-Chiari syndrome, congenital hepatic fibrosis, autosomal recessive polycystic kidney disease and non-cirrhotic portal hypertension – demonstrates the team's depth of expertise and ability to address complex medical needs quickly, before patients become too sick to transplant. "Achieving this milestone required tremendous dedication and teamwork," said Dr. Michael Wachs, Surgical Director of the Abdominal Transplant Program at Children's Colorado. "We have embraced cutting-edge advances, such as plasmapheresis and intraoperative dialysis for small children, allowing us to safely take on risks while maintaining excellent outcomes." The success of the Liver Transplant Program this past year would not have been possible without the steadfast support of Children's Colorado, UCHealth University of Colorado Hospital (UCHealth) and the unwavering commitment of the entire transplant team to deliver the lowest waitlist times in the country – less than two months, compared to the national average of eight months – and the best possible patient outcomes. As the program continues to grow, it is positioned to expand its reach and impact on a larger regional and national scale to help save the lives of more children. In partnership with UCHealth, any non-directed liver donor, or a person who donates a portion of their liver without knowing the person receiving the donation, will first be offered to a patient on the Children's Colorado waitlist. To be a living donor, one needs to be a healthy adult between the ages of 18-55. The donor does not need to be related to the recipient in any way to save their life. Surgeons at UCHealth are now able to perform the donor operation with robotic assistance, allowing for donors to be out of the hospital in just a few days. To learn more about the process of becoming a donor, go to UCHealth University of Colorado Hospital Transplant Center. For more information about pediatric liver transplants, visit Children's Colorado Liver Transplant Program. ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800. CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800. Media Contacts: Blayke Roznowski, Children's Hospital Colorado 24/7 media line: 303-890-8314 [email protected] SOURCE Children's Hospital Colorado WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter (hereinafter referred to as "ZENFlow Tiger™"), a product independently developed by the Company, has received marketing approval from ANVISA. The Company expects the launch of this newly approved product to provide a solid start to its business development in the South American market. ZENFlow Tiger™ has several outstanding features. Its braided delivery shaft provides outstanding pushability and kink resistance, while the low-temperature molding technology ensures excellent non-compliance. With its unique tapered tip and short shoulder design, ZENFlow Tiger™ can facilitate access through complex lesions and maximize protection of normal blood vessels. Additionally, a coaxial catheter shaft design allows ZENFlow Tiger™ to inflate and deflate rapidly, and it is available in a wide range of sizes for different clinical needs. The Company also expects ZENFlow Tiger™ to show advantages in the treatment of various vascular diseases, such as iliac vein compression syndrome, Budd-Chiari syndrome, and other peripheral vascular occlusions. When this product is properly used in combination with mechanical thrombectomy devices and peripheral stents, the Company expects to see better treatment efficacy. Driven by an aging population with greater awareness of treatment options, and the development of interventional technology, the peripheral vascular interventional devices market has continued to grow rapidly in recent years. By introducing ZENFlow Tiger™ into the Brazilian market, the Company expects to provide high-quality products and comprehensive solutions to local patients, and to continue to grow and succeed in its international business. In 2023, Zylox-Tonbridge has made great progress in overseas markets. The Company generated a revenue of 6.23 million yuan, representing a YOY increase of 128.7% during the first half of this year. As of the end of June, the Company's products have been successfully commercialized in several developed overseas markets. Leveraging its strong R&D capabilities and advanced manufacturing platforms, the Company also provided OEM services to local brands in some emerging markets. Looking forward, Zylox-Tonbridge plans to continue investing in the international markets, providing patients worldwide with more innovative medical device products and solutions. About Zylox-Tonbridge: Zylox-Tonbridge is one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China. The Company was founded in 2012 and is headquartered in Hangzhou, China. As an integrated medical device company supported by our in-house R&D and manufacturing capabilities, proprietary technological platforms, and commercialization capabilities, we strive to provide patients with high-quality and affordable medical devices and services, so that everyone has access to the high-quality life brought by advanced medical technology. For more information, please visit our official website: SOURCE ZYLOX-TONBRIDGE